Plasmodium Falciparum Erythrocyte Binding Protein Baebl For Use as a Vaccine

Type
Compound(s)

Malaria is endemic in many parts of the world, particularly in tropical regions such as Asia, Central America and South America. Recent estimates of the number of cases of malaria worldwide are between five hundred million and one billion. There are approximately two to three hundred million new cases of malaria each year and malaria causes a minimum of one million deaths each year. This invention relates to the identification and characterization of the binding specificity of BAEBL, a novel Plasmodium falciparum erythrocyte binding ligand that interacts with human erythrocytes in a sialic acid dependent manner. This novel Plasmodium falciparum erythrocyte binding ligand is unique and quite distinct from previously described Plasmodium falciparum erythrocyte binding proteins EBA-175. BAEBL may be used as a malaria vaccine to block human red cell recognition and invasion.

Disease
Malaria
Research areas
Basic research
Vaccine
Condition of use

n/a

IP information

Abandoned Patent Reference Number(s): WO/02/078603/Abandoned HHS, Reference No. E-328-2000/0-US-03; All abandoned; US, , Application Number 10/677,980, Filed 02 Oct 2003